



**Supplementary Figure.1.** Intratumoral ISF35 suppresses BP melanoma. Mice bearing 7-day s.c. BP tumors (derived from BRAF<sup>V600E</sup>xPTEN<sup>-/-</sup> melanoma prone-mice) were treated as indicated, graph depicts long term survival(n=7). Survival analysis was performed with the log-rank test

a



b



**Supplementary Figure.2.** Anti-tumor effect of intratumoral ISF35 and anti-PD-1 or anti-CTLA-4 antibody combination therapy. (a) Mice bearing 7-day s.c. B16.F10 tumors were treated as indicated, graph depicts long term survival(n=20) (b) Mice bearing 7 day old right flank tumor and 5 days old left flank tumor were treated only in the right flank tumor with ISF35 and received anti-PD-1 i.p. Graphs depict growth of ISF35-injected or uninjected opposite tumors. Data is analyzed by unpaired two-tailed t test. \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.0005$ , \*\*\*\* $p < 0.0001$  (n=5 to 7 mice). Error bars are SEM. Survival analysis was performed with the log-rank test